Medic Life Sciences

Executive Summary

Medic Life Sciences (MEDiC) is a San Diego-based biotechnology company pioneering a novel oncology drug discovery platform that integrates CRISPR functional genomics with patient-derived 3D tumor-immune co-culture models. By systematically unraveling the genetic determinants of therapeutic response, MEDiC aims to identify high-confidence drug targets, biomarkers, synthetic lethality interactions, and resistance mechanisms. This approach addresses a critical bottleneck in cancer drug development: the high failure rate due to insufficient understanding of tumor biology and patient heterogeneity. The platform’s ability to model the tumor microenvironment and immune interactions positions MEDiC to generate more predictive preclinical data, increasing the probability of clinical success for its future pipeline candidates. Founded in 2018, the company operates in the fast-growing precision oncology space, where its differentiated technology could enable more efficient discovery of novel therapies for underserved patient populations. MEDiC’s strategy focuses on leveraging its proprietary platform to build a portfolio of preclinical assets while also pursuing partnerships with pharmaceutical and biotech companies seeking to de-risk their own oncology programs. Although the company is still in early stages with no disclosed funding or pipeline details, its innovative approach and experienced team suggest significant potential. If successful, MEDiC could become a key player in precision oncology by accelerating the identification of effective drug combinations and reducing late-stage attrition. The upcoming catalysts will likely center on platform validation and capital raise activities that could propel the company toward IND-enabling studies.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round70% success
• Q4 2026Partnership with Major Pharma for Target Discovery60% success
• Q2 2026Publication of Platform Validation Data in Peer-Reviewed Journal80% success